GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Wang, Zaozao ^a   Jiang, Beihai ^a   Chen, Lei ^a   Di, Jiabo ^a   Cui, Ming ^a   Liu, Maoxing ^a   Ma, Yiyuan ^a   Yang, Hong ^a   Xing, Jiadi ^a   Zhang, Chenghai ^a   Yao, Zhendan ^a   Zhang, Nan ^a   Dong, Bin ^a   Ji, Jiafu ^a   Su, Xiangqian ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

5 fluorouracil (5 FU); Chemotherapy; Colorectal cancer (CRC); GOLPH3; Prognosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PROTEIN GOLPH3; SMALL INTERFERING RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CELL DEATH; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; RNA, SMALL INTERFERING;

EID: 84892609573     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-15     Document Type: Article

References (28)

1. Qaseem A, Denberg TD, Hopkins RH, Humphrey LL, Levine J, Sweet DE, Shekelle P. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012, 156:378-386. 10.7326/0003-4819-156-5-201203060-00010, 22393133.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet 2010, 375:1030-1047. 10.1016/S0140-6736(10)60353-4, 20304247.
3. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338. 10.1038/nrc1074, 12724731.
4. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18:136-147.
5. Gholam D, Giacchetti S, Brezault-Bonnet C, Bouchahda M, Hauteville D, Adam R, Ducot B, Ghemard O, Kustlinger F, Jasmin C, Levi F. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist 2006, 11:1072-1080. 10.1634/theoncologist.11-10-1072, 17110626.
6. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005, 205:275-292. 10.1002/path.1706, 15641020.
7. Bell AW, Ward MA, Blackstock WP, Freeman HN, Choudhary JS, Lewis AP, Chotai D, Fazel A, Gushue JN, Paiement J, et al. Proteomics characterization of abundant Golgi membrane proteins. J Biol Chem 2001, 276:5152-5165. 10.1074/jbc.M006143200, 11042173.
8. Dippold HC, Ng MM, Farber-Katz SE, Lee SK, Kerr ML, Peterman MC, Sim R, Wiharto PA, Galbraith KA, Madhavarapu S, et al. GOLPH3 bridges phosphatidylinositol-4- phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell 2009, 139:337-351. 10.1016/j.cell.2009.07.052, 2779841, 19837035.
9. Scott KL, Chin L. Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis. Clin Cancer Res 2010, 16:2229-2234. 10.1158/1078-0432.CCR-09-1695, 2855764, 20354134.
10. Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009, 459:1085-1090. 10.1038/nature08109, 2753613, 19553991.
11. Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, Chen K, Li J, Song L. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res 2012, 18:4059-4069. 10.1158/1078-0432.CCR-11-3156, 22675169.
12. Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, Lin HX, Chen K, Li J, Yun JP, et al. High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PLoS One 2012, 7:e45622. 10.1371/journal.pone.0045622, 3462781, 23056210.
13. Li H, Guo L, Chen SW, Zhao XH, Zhuang SM, Wang LP, Song LB, Song M. GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med 2012, 10:168. 10.1186/1479-5876-10-168, 3480894, 22905766.
14. Hu BS, Hu H, Zhu CY, Gu YL, Li JP. Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol 2013, 34:515-520. 10.1007/s13277-012-0576-z, 23132295.
15. Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L, Shen H. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol 2012, 7:127. 10.1186/1746-1596-7-127, 3488508, 23006319.
16. Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen Y, Yu H, Xia C, Lu Y, Ding X, et al. Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol 2012, 110:195-203. 10.1007/s11060-012-0970-9, 22972189.
17. Li XY, Liu W, Chen SF, Zhang LQ, Li XG, Wang LX. Expression of the Golgi phosphoprotein-3 gene in human gliomas: a pilot study. J Neurooncol 2011, 105:159-163. 10.1007/s11060-011-0573-x, 21499727.
18. Kunigou O, Nagao H, Kawabata N, Ishidou Y, Nagano S, Maeda S, Komiya S, Setoguchi T. Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Rep 2011, 26:1337-1342.
19. Han HB, Gu J, Zuo HJ, Chen ZG, Zhao W, Li M, Ji DB, Lu YY, Zhang ZQ. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol 2012, 226:544-555. 10.1002/path.3014, 21984339.
20. Chen L, Jiang B, Wang Z, Liu M, Ma Y, Yang H, Xing J, Zhang C, Yao Z, Zhang N, et al. Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer. Med Oncol 2013, 30:498.
21. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147:344-357. 10.1016/j.cell.2011.09.029, 3235920, 22000013.
22. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, De Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998, 273:33533-33539. 10.1074/jbc.273.50.33533, 9837934.
23. Shiozaki A, Kosuga T, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Iitaka D, Nakashima S, Shimizu H, Ishimoto T, et al. XB130 as an independent prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol 2013, 20:3140-3150. 10.1245/s10434-012-2474-4, 22805860.
24. Lodyga M, Bai XH, Kapus A, Liu M. Adaptor protein XB130 is a Rac-controlled component of lamellipodia that regulates cell motility and invasion. J Cell Sci 2010, 123:4156-4169. 10.1242/jcs.071050, 21084565.
25. Shiozaki A, Lodyga M, Bai XH, Nadesalingam J, Oyaizu T, Winer D, Asa SL, Keshavjee S, Liu M. XB130, a novel adaptor protein, promotes thyroid tumor growth. Am J Pathol 2011, 178:391-401. 10.1016/j.ajpath.2010.11.024, 3070596, 21224076.
26. Shi M, Huang W, Lin L, Zheng D, Zuo Q, Wang L, Wang N, Wu Y, Liao Y, Liao W. Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer. PLoS One 2012, 7:e41660. 10.1371/journal.pone.0041660, 3426513, 22927913.
27. Lu D, Chen S, Tan X, Li N, Liu C, Li Z, Liu Z, Stupack DG, Reisfeld RA, Xiang R. Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy. Cancer Res 2012, 72:3451-3456. 10.1158/0008-5472.CAN-11-2536, 22586064.
28. Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res 2010, 70:3239-3248. 10.1158/0008-5472.CAN-09-3186, 2999007, 20388787.